External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><div><div><ul><li>PXS continues to make good progress developing its drug candidates.</li><li>It has reported encouraging initial evidence that its anti-fibrosis drug PXS-6302 improves patient scars and is expected to report initial data from the ongoing trial of PXS-5505 in myelofibrosis (MF) before the end of the year.</li><li>It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s disease (PD). </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PXS continues to make good progress developing its drug candidates.It has reported encouraging initial evidence that its anti-fibrosis drug PXS-6302 improves patient scars and is expected to report initial data from the ongoing trial of PXS-5505 in myelofibrosis (MF) before the end of the year.It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s disease (PD). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaxis (PXS) - Encouraging Initial Efficacy Data, Adding New Programs

Syntara

Pharmaxis (PXS) - Encouraging Initial Efficacy Data, Adding New Programs